The Technical Analyst
Cleveland Biolabs Inc [CBLI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cleveland Biolabs Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.31% $3.17
America/New_York / 1 sep 2021 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 226.39 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Aug 16, 2021 |
| SharesOutstanding: | 71.42 mill |
| Avg Daily Volume: | 0.157 mill |
| RATING 2022-02-09 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/20 | 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.73 - 3.61 ( +/- 13.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-07-27 | Selsky Clifford | Buy | 101 579 | Common Stock, par value $0.005 per share |
| 2021-07-27 | Aronstam Peter | Buy | 141 370 | Common Stock, par value $0.005 per share |
| 2021-07-27 | Selsky Clifford | Buy | 0 | |
| 2021-07-27 | Aronstam Peter | Buy | 0 | |
| 2021-07-27 | Barbarick Steve K | Buy | 0 |
| INSIDER POWER |
|---|
| 0.00 |
| Last 91 transactions |
| Buy: 2 702 906 | Sell: 404 086 |
Forecast:
01:40 - $3.62
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.17 (-7.31% ) |
| Volume | 0.116 mill |
| Avg. Vol. | 0.157 mill |
| % of Avg. Vol | 74.07 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CBLI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CBLI
Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
Latest Press Releases
2021-08-16 07:30:00 - Press Release
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
Fort collins, colo., aug. 16, 2021 /prnewswire/ -- cytocom, inc. (nasdaq: cbli), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the company for the second quarter ended june 30, 2021, a period of time prior to the completion of the merger between legacy cleveland biolabs and the formerly private cytocom inc. following the completion of the merger on july 27, 2021, cytocom, inc. emerged as a publicly traded entity.
2021-08-11 07:30:00 - Press Release
Cytocom, Inc. Announces Participation At Liberty University's Empowering The Kingdom Through Business Conference
Fort collins, colo., aug. 11, 2021 /prnewswire/ -- cytocom, inc. (nasdaq: cbli), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the empowering the kingdom through business conference hosted by the liberty university school of business on august 10-12, 2021.
2021-08-10 07:30:00 - Press Release
Cytocom, Inc. To Report Second Quarter 2021 Financial Results
Fort collins, colo., aug. 10, 2021 /prnewswire/ -- cytocom, inc. (nasdaq: cbli), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will host a conference call and live audio webcast on monday, august 16, 2021, at 8:30 a.m.
2021-08-09 07:30:00 - Press Release
Cytocom Inc. Provides Updates On Key Clinical Programs For Crohn's Disease, Hematology, Pancreatic Cancer And Covid-19
Fort collins, colo., aug. 9, 2021 /prnewswire/ -- cytocom inc. (nasdaq: cbli), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs.
2021-08-05 07:33:00 - Press Release
Cytocom Inc. Provides Update On Completed Merger With Cleveland Biolabs
Fort collins, colo., aug. 5, 2021 /prnewswire/ -- cytocom inc. (nasdaq: cbli), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with cleveland biolabs.
Latest News
2021-08-16 11:22:03 - Seeking Alpha
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
2021-08-16 07:30:00 - PRNewsWire
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.
2021-08-11 07:30:00 - PRNewsWire
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021.
2021-08-10 07:30:00 - PRNewsWire
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m.
2021-08-09 07:30:00 - PRNewsWire
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs.
2021-08-05 07:33:00 - PRNewsWire
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.
2021-07-29 07:33:00 - PRNewsWire
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital.
2021-07-06 09:16:00 - PRNewsWire
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
2021-06-18 05:58:23 - Pulse2
CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Cleveland BioLabs, Inc. (Nasdaq: CBLI) increased by over 15% pre-market. This is why it happened.
2021-06-17 18:37:00 - PRNewsWire
Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
